Pharmacotherapy of asthma: Regular treatment or on demand?

Therapeutic Advances in Respiratory Disease

Volumn 3, Issue 4, 2009, Pages 175-191

  Montuschi, Paolo ^a   Pagliari, Gabriella ^a   Fuso, Leonello ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

airway inflammation; asthma; inhaled corticosteroids; leukotriene receptor antagonists; long acting beta agonists; on demand pharmacological therapy; regular pharmacological therapy

Indexed keywords

BECLOMETASONE DIPROPIONATE; BECLOMETASONE DIPROPIONATE PLUS SALBUTAMOL; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHROMONE DERIVATIVE; CORTICOSTEROID DERIVATIVE; CROMOGLYCATE DISODIUM; FLUTICASONE; FORMOTEROL; IMMUNOGLOBULIN E ANTIBODY; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING DRUG; MONTELUKAST; MUSCARINIC RECEPTOR BLOCKING AGENT; NEDOCROMIL; OMALIZUMAB; PLACEBO; PREDNISONE; SALBUTAMOL; SALMETEROL; SHORT ACTING DRUG; TERBUTALINE; THEOPHYLLINE DERIVATIVE; UNINDEXED DRUG; ZAFIRLUKAST; ZILEUTON;

ADD ON THERAPY; ADRENAL SUPPRESSION; ALLERGIC ASTHMA; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BONE DEMINERALIZATION; BRONCHOSPASM; CANDIDIASIS; CATARACT; CHILDHOOD DISEASE; CHRONIC DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST UTILITY ANALYSIS; DISEASE CLASSIFICATION; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EXCRETION; DRUG FATALITY; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; FORCED EXPIRATORY VOLUME; GROWTH INHIBITION; GROWTH RETARDATION; HEART PALPITATION; HOARSENESS; HUMAN; INTRAOCULAR HYPERTENSION; LARYNX DISORDER; LOW DRUG DOSE; LUNG FUNCTION; MONOTHERAPY; NONHUMAN; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PEAK EXPIRATORY FLOW; PHARYNX DISEASE; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; REVIEW; SIDE EFFECT; SORE THROAT; TACHYCARDIA; TOXIC HEPATITIS; TREATMENT DURATION; TREATMENT PLANNING; TREATMENT RESPONSE; TREMOR; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTI-ASTHMATIC AGENTS; ANTI-INFLAMMATORY AGENTS; ASTHMA; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION SCHEDULE; HUMANS; PHENOTYPE; PRACTICE GUIDELINES AS TOPIC;

EID: 70349501414     PISSN: 17534658     EISSN: None     Source Type: Journal    
DOI: 10.1177/1753465809343711     Document Type: Review

References (99)

1. Agertoft, L. and Pedersen, S. (2000) Effects of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med 343: 1064-1069.
2. Bateman, E.D., Boushey, H.A., Bousquet, J., Busse, W.W., Clark, T.J., Pauwels, R.A. et al. (2004) Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL (GOAL) study. Am J Respir Crit Care Med 170: 836-844.
3. Bateman, E., Nelson, H., Bousquet, J., Kral, K., Sutton, L., Ortega, H. et al. (2008) Meta-analysis: effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events. Ann Intern Med 149: 33-42.
4. Bisgaard, H., Hermansen, M.N., Loland, L., Halkjaer, L.B. and Buchvald, F. (2006) Intermittent inhaled corticosteroids in infants with episodic wheezing. N Engl J Med 354: 1998-2005.
5. Bjermer, L., Bisgaard, H., Bousquet, J., Fabbri, L., Greening, A.P., Haahtela, T. et al. (2003) Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: oner year, double blind, randomised, comparative trial. BMJ 327: 891.
6. Bleecker, E.R., Postma, D.S., Lawrance, R.M., Meyers, D.A., Ambrose, H.J. and Goldman, M. (2007) Effect of ADRB2 polymorphisms on response to long acting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet 370: 2118-2125.
7. Bleecker, E.R., Welch, M.J., Weinstein, S.F., Kalberg, C., Johnson, M., Edwards, L. et al. (2000) Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma. J Allergy Clin Immunol 105: 1123-1129.
8. Bleecker, E.R., Yancey, S.W., Baitinger, L.A., Edwards, L.D., Klotsman, M., Anderson, W.H. et al. (2006) Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma. J Allergy Clin Immunol 118: 809-816.
9. Boulet, L.P., Cartier, A., Milot, J., Côté, J., Malo, J.L. and Laviolette, M. (1998) Tolerance to the protective effects of salmeterol on methacholine-induced bronchoconstriction: influence of inhaled corticosteroids. Eur Respir J 11: 1091-1097.
10. Boushey, H.A., Sorkness, C.A., King, T.S., Sullivan, S.D., Fahy, J.V., Lazarus, S.C. et al. (2005) Daily versus as-needed corticosteroids for mild persistent asthma. N Engl J Med 352: 1519-1528.
11. Bukstein, D.A., Bratton, D.L., Firriolo, K.M., Estojak, J., Bird, S.R., Hustad, C.M. et al. (2003) Evaluation of parental preference for the treatment of asthmatic children aged 6 to 11 years with oral montelukast or inhaled cromolyn: a randomized, open-label, crossover study. J Asthma 40: 475-485.
12. Busse, W., Corren, J., Lanier, B.Q., McAlary, M., Fowler-Taylor, A., Della Cioppa, G. et al. (2001) Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 108: 184-190.
13. Canonica, G.W. (2006) Treating asthma as an inflammatory disease. Chest 130: 21S-28S.
14. Castro-Rodriguez, J.A. and Rodrigo, G.J. (2009) Efficacy of inhaled corticosteroids in infants and preschoolers with recurrent wheezing and asthma: a systematic review and meta-analysis. Pediatrics 123: e519-e525.
15. Childhood Asthma Management Program Research Group (2000) Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med 343: 1054-1063.
16. Dahlen, B., Nizankowska, E., Szczeklik, A., Zetterström, O., Bochenek, G., Kumlin, M. et al. (1998) Benefits from adding the5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med 157: 1187-1194.
17. Donahue, J.G., Weiss, S.T., Livingston, J.M., Goetsch, M.A., Greineder, D.K. and Platt, R. (1997) Inhaled steroids and the risk of hospitalization for asthma. JAMA 277: 887-891.
18. Ducharme, F.M., Lasserson, T.J. and Cates, C.J. (2006) Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev CD003137.
19. Edelman, J.M., Turpin, J.A., Bronsky, E.A., Grossman, J., Kemp, J.P., Ghannam, A.F. et al. (2000) Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. A randomized, double-blind trial. Ann Intern Med 132: 97-104.
20. Ernst, P., Habbick, B., Suissa, S., Hemmelgarn, B., Cockcroft, D., Buist, A.S. et al. (1993) Is the association between inhaled beta-agonist use and life-threatening asthma because of confounding by severity? Am Rev Respir Dis 148: 75-79.
21. Evans, D.J., Taylor, D.A., Zetterstrom, O., Chung, K.F., O–Connor, B.J. and Barnes, P.J. (1997) A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med 337: 1412-1418.
22. Fabbri, L.M. (2005) Does mild persistent asthma require regular treatment? N Engl J Med 352: 1589-1591.
23. Fanta, C.H. (2009) Asthma. N Engl J Med 360: 1002-1014.
24. Gibson, P.G., Powell, H. and Ducharme, F. (2005) Long-acting beta2-agonists as an inhaled corticosteroids-sparing agent for chronic asthma in adults and children. Cochrane Database Syst Rev CD005076.
25. Giembycz, M.A., Kaur, M., Leigh, R. and Newton, R. (2008) A Holy Grail of asthma management: toward understanding how long-acting beta2-adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids. Br J Pharmacol 153: 1090-1104.
26. Gina (2008) Global Initiative for Asthma. Global strategy for asthma management and prevention. Update 2008. Available at: www.ginasthma.com
27. Greenstone, I.R., Ni Chroinin, M.N., Masse, V., Danish, A., Magdalinos, H., Zhang, X. et al. (2005) Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma. Cochrane Database Syst Rev CD005533.
28. Grove, A. and Lipworth, B.J. (1995) Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. Lancet 346: 201-206.
29. Guevara, J.P., Ducharme, F.M., Keren, R., Nihtianova, S. and Zorc, J. (2006) Inhaled corticosteroids versus sodium cromoglycate in children and adults with asthma. Cochrane Database Syst Rev CD003558.
30. Guilbert, T.W., Morgan, W.J., Zeiger, R.S., Mauger, D.T., Boehmer, S.J., Szefler, S.J. et al. (2006) Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med 354: 1985-1997.
31. Haahtela, T., Jarvinen, M., Kava, T., Kiviranta, K., Koskinen, S., Lehtonen, K. et al. (1994) Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med 331: 700-705.
32. Hall, I.P. (2006) Pharmacogenetics of asthma. Chest 130: 1873-1878.
33. Haney, S. and Hancox, R.J. (2005) Rapid onset of tolerance to beta-agonist bronchodilation. Respir Med 99: 566-571.
34. Hauser, T., Mahr, A., Metzler, C., Coste J., Sommerstein, R., Gross, W.L. et al. (2008) The leukotriene-receptor antagonist montelukast and the risk of Churg-Strauss syndrome: a case-crossover study. Thorax 63: 677-682.
35. Henderson Jr, W.R., Chiang, G.K., Tien, Y.T. and Chi, E.Y. (2006) Reversal of allergen-induced airway remodeling by cysLT1 receptor blockade. Am J Respir Crit Care Med 173: 718-728.
36. Hoag, J.E. and McFadden Jr, E.R. (1991) Long-term effect of cromolyn sodium on non-specific bronchial hyperresponsiveness: a review. Ann Allergy 66: 53-63.
37. Holgate, S.T. (2001) Therapeutic options for persistent asthma. JAMA 285: 2637-2639.
38. Holgate, S., Buhl, R., Bousquet, J., Smith, N., Panahloo, Z. and Jimenez, P. (2009) The use of omalizumab in the treatment of severe allergic asthma: A clinical experience update. Respir Med 103: 1098-1113.
39. Hoshino, M., Takahashi, M., Takai, Y. and Sim, J. (1999) Inhaled corticosteroids decrease subepithelial collagen deposition by modulation of the balance between matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 expression in asthma. J Allergy Clin Immunol 103: 1054-1061.
40. Humbert, M., Beasley, R., Ayres, J., Slavin, R., Hébert, J., Bousquet, J. et al. (2005) Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy. Allergy 60: 309-316.
41. Irwin, R.S. and Richardson, N.D. (2006) Side effects with inhaled corticosteroids: the physician's perception. Chest 130(1 Suppl): 41S-53S.
42. Israel, E., Chinchilli, V.M., Ford, J.G., Boushey, H.A., Cherniack, R., Craig, T.J. et al. (2004) Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 364: 1505-1512.
43. Israel, E., Drazen, J.M., Liggett, S.B., Boushey, H.A., Cherniack, R.M., Chinchilli, V.M. et al. (2000) The effect of polymorphisms of the beta2-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 162: 75-80.
44. James, A.L., Palmer, L.J., Kicic, E., Maxwell, P.S., Lagan, S.E., Ryan, G.F. et al. (2005) Decline in lung function in the Busselton Health Study: the effects of asthma and cigarette smoking. Am J Respir Crit Care Med 171: 109-114.
45. Kelly, M.M., Chakir, J., Vethanayagam, D., Boulet, L.P., Laviolette, M., Gauldie, J. et al. (2006) Montelukast treatment attenuates the increase in myofibroblasts following low-dose allergen challenge. Chest 130: 741-753.
46. Kips, J.C. and Pauwels, R.A. (2001) Long-acting inhaled beta2-agonist therapy in asthma. Am J Respir Crit Care Med 164: 923-932.
47. Kramer, J.M. (2009) Balancing the benefits and risks of inhaled long-acting beta-agonists. The influence of values. N Engl J Med 360: 1592-1595.
48. Lange, P., Parner, J., Vesto, J., Schnohr, P. and Jensen, G. (1998) A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med 339: 1194-1200.
49. Latimer, K.M., O–Byrne, P.M., Morris, M.M., Roberts, R. and Hargreave, F.E. (1983) Bronchoconstriction stimulated by airway cooling: better protection with combined inhalation of terbutaline sulphate and cromolyn sodium than either alone. Am Rev Respir Dis 128: 440-443.
50. Lazarus, S.C. (2006) Mild persistent asthma: is any treatment needed? J Allergy Clin Immunol 118: 805-808.
51. Lazarus, S.C., Chinchilli, V.M., Rollings, N.J., Boushey, H.A., Cherniack, R., Craig, T.J. et al. (2007) Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am J Respir Crit Care Med 175: 783-790.
52. Lemanske Jr, R.F., Sorkness, C.A., Mauger, E.A., Lazarus, S.C., Boushey, H.A., Fahy, J.V. et al. (2001) Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. JAMA 285: 2594-2603.
53. Lipworth, B.J. (2007) Long-acting beta2-adrenoceptor agonists: a smart choice for asthma? Trends Pharmacol Sci 28: 257-262.
54. Lommatzsch, M., Lindner, Y., Edner, A., Bratke, K., Kuepper, M. and Virchow, J.C. (2009) Adverse effects of salmeterol in asthma: a neuronal perspective. Thorax Feb 22 [Epub ahead of print].
55. Lommatzsch, M., Schloetcke, K., Klotz, J., Schuhbaeck, K., Zingler, D., Zingler, C. et al. (2005) Brain-derived neurotrophic factor in platelets and airflow limitation in asthma. Am J Respir Crit Care Med 171: 115-120.
56. Masoli, M., Weatherall, M., Holt, S. and Beasley, R. (2005) Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma. Thorax 60: 730-734.
57. McIvor, R.A., Pizzichini, E., Turner, M.O., Hussack, P., Hargreave, F.E. and Sears, M.R. (1998) Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med 158: 924-930.
58. Montuschi, P., Sala, A., Dahlén, S.E. and Folco, G. (2007) Pharmacological modulation of the leukotriene pathway in allergic airway disease. Drug Discov Today 12: 404-412.
59. Montuschi, P. (2008) Leukotrienes, antileukotrienes and asthma. Mini Rev Med Chem 8: 647-656.
60. Mullen, M., Mullen, B. and Carey, M. (1993) The association between beta-agonist use and death from asthma. A meta-analytic integration of case-control studies. JAMA 270: 1842-1845.
61. Naepp (2007) National Asthma Education and Prevention Program: Expert panel report III. Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute (NIH publication no. 08-4051). Available at: www.nhlbi.nih.gov
62. Nelson, H.S. (1995) Beta-adrenergic bronchodilators. N Engl J Med 333: 499-506.
63. Nelson, H.S., Weiss, S.T., Bleecker, E.R., Yancey, S.W. and Dorinsky, P.M. (2006) The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 129: 15-26.
64. Ni Chroinin, M., Greenstone, I.R., Danish, A., Magdolinos, H., Masse, V., Zhang, X. et al. (2005) Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma. Cochrane Database Syst Rev CD005535.
65. O–Byrne, P.M., Barnes, P.J., Rodriguez-Roisin, R., Runnerstrom, E., Sandstrom, T., Svensson, K. et al. (2001) Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 164: 1392-1397.
66. O–Byrne, P.M., Bisgaard, H., Godard, P.P., Pistolesi, M., Palmqvist, M., Zhu, Y. et al. (2005) Budesonide/ formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 171: 129-136.
67. O–Byrne, P.M. and Kerstjens, H.A. (1996) Inhaled beta2-agonists in the treatment of asthma. N Engl J Med 335: 886-888.
68. O–Byrne, P.M., Pedersen, S., Busse, W.W., Tan, W.C., Chen, Y.Z., Ohlsson, S.V. et al. (2006) Effects of early intervention with inhaled budesonide on lung function in newly diagnosed asthma. Chest 129: 1478-1485.
69. O–Byrne, P.M., Pedersen, S., Lamm, C.J., Tan, W.C. and Busse, W.W. (2009) Severe exacerbations and decline in lung function in asthma. Am J Respir Crit Care Med 179: 19-24.
70. Papi, A., Canonica, G.W., Maestrelli, P., Paggiaro, P., Olivieri, D., Pozzi, L. et al. (2007) Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med 356: 2040-2052.
71. Pauwels, R.A., Lofdahl, C.G., Postma, D.S., Tattersfield, A.E., O–Byrne, P., Barnes, P.J. et al. (1997) Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 337: 1405-1411.
72. Pauwels, R.A., Pedersen, S., Busse, W.W., Tan, W.C., Chen, Y.Z., Ohlsson, S.V. et al. (2003) Early intervention with budesonide in mild persistent asthma: a randomized, double-blind trial. Lancet 361: 1071-1076.
73. Peters-Golden, M., Swern, A., Bird, S.S., Hustad, C.M., Grant, E. and Edelman, J.M. (2006) Influence of body mass index on the response to asthma controller agents. Eur Respir J 27: 495-503.
74. Petsky, H.L., Kynaston, J.A., Turner, C., Li, A.M., Cates, C.J., Lasserson, T.J. et al. (2007) Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults. Cochrane Database Syst Rev 2: CD005603.
75. Price, D.B., Hernandez, D., Magyar, P., Fiterman, J., Beeh, K.M., James, I.G. et al. (2003) Randomized controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax 58: 211-216.
76. Reiss, T.F., Chervinsky, P., Dockhorn, R.J., Shingo, S., Seidenberg, B. and Edwards, T.B. (1998) Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double blind trial. Arch Intern Med 158: 1213-1220.
77. Salpeter, S.R., Ormiston, T.M. and Salpeter, E.E. (2004) Meta-analysis: respiratory tolerance to regular beta2-agonist use in patients with asthma. Ann Intern Med 140: 802-813.
78. Sears, M.R., Ottosson, A., Radner, F. and Suissa, S. (2009) Long-acting beta-agonists: a review of formoterol safety data from asthma clinical trials. Eur Respir J 33: 21-32.
79. Sears, M.R., Taylor, D.R., Print, C.G., Lake, D.C., Li, Q.Q., Flannery, E.M. et al. (1990) Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 336: 1391-1396.
80. Selroos, O., Pietinalho, A., Lofroos, A.B. and Riska, H. (1995) Effect of early vs late intervention with inhaled corticosteroids in asthma. Chest 108: 1228-1234.
81. Silkoff, P.E., Carlson, M., Bourke, T., Katial, R., Ogren, E. and Szefler, S.J. (2004) The Aerocrine exhaled nitric oxide monitoring system NIOX is cleared by the US Food and Drug Administration for monitoring therapy in asthma. J Allergy Clin Immunol 114: 1241-1256.
82. Sindi, A., Todd, D.C. and Nair, P. (2009) Antiinflammatory effects of long-acting beta2-agonists in patients with asthma: a systematic review and metaanalysis. Chest 136: 145-154.
83. Sovijarvi, A.R., Haahtela, T., Ekroos, H.J., Lindqvist, A., Saarinen, A., Poussa, T. et al. (2003) Sustained reduction in bronchial hyperresponsiveness with inhaled fluticasone propionate within three days in mild asthma: time course after onset and cessation of treatment. Thorax 58: 500-504.
84. Spitzer, W.O., Suissa, S., Ernst, P., Horwitz, R.I., Habbick, B., Cockcroft, D. et al. (1992) The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med 326: 501-506.
85. Sridhar, A.V. and McKean, M. (2006) Nedocromil sodium for chronic asthma in children. Cochrane Database Syst Rev CD004108.
86. Storms, W., Chervinsky, P., Ghannam, A.F., Bird, S., Hustad, C.M., Edelman, J.M. et al. (2004) A comparison of the effects of oral montelukast and inhaled salmeterol on response to rescue bronchodilation after challenge. Respir Med 98: 1051-1062.
87. Suissa, S., Ernst, P., Benayoun, S., Baltzan, M. and Cai, B. (2000) Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 343: 332-336.
88. Szefler, S.J., Martin, R.J., King, T.S., Boushey, H.A., Cherniack, R.M., Chinchilli, V.M. et al. (2002) Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol 109: 410-418.
89. Tamaoki, J., Kondo, M., Sakai, N., Nakata, J., Takemura, H., Nagai, A. et al. (1997) Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. Am J Respir Crit Care Med 155: 1235-1240.
90. Taylor, D.R., Drazen, J.M., Herbison, G.P., Yandava, C.N., Hancox, R.J. and Town, G.I. (2000) Asthma exacerbations during long-term beta agonist use: influence of beta2-adrenoceptor polymorphism. Thorax 55: 762-767.
91. Taylor, D.R., Bateman, E.D., Boulet, L.P., Boushey, H.A., Busse, W.W., Casale, T.B. et al. (2008) A new perspective on concepts of asthma severity and control. Eur Respir J 32: 545-554.
92. Tomlinson, J.E., McMahon, A.D., Chaudhuri, R., Thompson, J.M., Wood, S.F. and Thomson, N.C. (2005) Efficacy of low and high dose inhaled corticosteroid in smokers versus non-smokers with mild asthma. Thorax 60: 282-287.
93. Turpeinen, M., Nikander, K., Pelkonen, A.S., Syvanen, P., Sorva, R., Raitio, H. et al. (2008) Daily versus as-needed inhaled corticosteroid for mild persistent asthma. The Helsinki early intervention childhood asthma study. Arch Dis Child 93: 654-659.
94. Van den Toorn, L.M., Overbeek, S.E., de Jongste, J.C., Leman, K., Hoogsteden, H.C. and Prins, J.B. (2001) Airway inflammation is present during clinical remission of atopic asthma. Am J Respir Crit Care Med 164: 2107-2113.
95. Vaquerizo, M.J., Casan, P., Castillo, J., Perpiña, M., Sanchis, J., Sobradillo, V. et al. (2003) Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax 58: 204-210.
96. Ward, C., Pais, M., Bish, R., Reid, D., Feltis, B., Johns, D. et al. (2002) Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma. Thorax 57: 309-316.
97. Wechsler, M.E., Lehman, E., Lazarus, S.C., Lemanske Jr, R.F., Boushey, H.A., Deykin, A. et al. (2006) Beta-adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med 173: 519-526.
98. Wolfe, J., Laforce, C., Friedman, B., Sokol, W., Till, D., Della Cioppa, G. et al. (2006) Formoterol, 24 mcg bid, and serious asthma exacerbations: similar rates compared with formoterol, 12 mcg bid, with and without extra doses taken on demand, and placebo. Chest 129: 27-36.
99. Woolcock, A., Lundback, B., Ringdal, N. and Jacques, L.A. (1996) Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 153: 1481-1488.